Loading...
•
Mar 31, 2025
Bioxcel Therapeutics Q1 2025 Earnings Report
BioXcel Therapeutics reported its financial results for the first quarter of 2025, with a net loss of $7.3 million and a decrease in revenue compared to the previous year, while also announcing the full enrollment of its SERENITY At-Home pivotal Phase 3 safety trial.
Key Takeaways
BioXcel Therapeutics reported a net loss of $7.3 million for the first quarter of 2025, a significant improvement from the $26.8 million net loss in the same period of 2024. Revenue from IGALMI® decreased to $168,000 from $582,000 year-over-year. The company also announced the full enrollment of its SERENITY At-Home pivotal Phase 3 safety trial, with topline data expected in the second half of 2025.
Net loss significantly improved to $7.3 million in Q1 2025 from $26.8 million in Q1 2024.
Product revenue from IGALMI® decreased to $168,000 in Q1 2025 from $582,000 in Q1 2024.
Research and Development expenses decreased to $4.6 million in Q1 2025 from $11.4 million in Q1 2024, primarily due to reduced clinical trial activity and personnel costs.
Selling, General and Administrative expenses decreased to $5.7 million in Q1 2025 from $13.3 million in Q1 2024, driven by lower personnel, professional fees, and marketing costs.
SERENITY At-Home pivotal Phase 3 safety trial is fully enrolled, with topline data anticipated in the second half of 2025.
Revenue by Segment
Forward Guidance
The company anticipates topline data from the SERENITY At-Home Phase 3 trial in the second half of 2025, which is intended to support a potential sNDA submission for label expansion of IGALMI® in the at-home setting. The TRANQUILITY In-Care Phase 3 trial remains part of the development strategy, with plans for trial initiation advancing.
Positive Outlook
- Topline data for SERENITY At-Home Phase 3 trial expected in second half of 2025.
- Potential sNDA submission for label expansion of IGALMI® in the at-home setting.
- Advancing plans for TRANQUILITY In-Care Phase 3 trial initiation.
- Opportunity to expand the market potential of IGALMI® to millions of additional patients.
- Continuing to supply IGALMI® to patients and providers and build brand awareness with minimal commercial resources.
Challenges Ahead
- The safety and effectiveness of BXCL501 for investigational uses have not been established.
- The Company's ability to realize its expectations and beliefs is inherently uncertain.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...